Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines

Treatment of patients with advanced sarcoma remains challenging due to lack of effective medicine, with the development of novel drugs being of keen interest. A pan-PI3K inhibitor, ZSTK474, has been evaluated in clinical trials against a range of advanced solid tumors, with clinical benefit shown in...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Namatame, Nachi, Tamaki, Naomi, Yoshizawa, Yuya, Okamura, Mutsumi, Nishimura, Yumiko, Yamazaki, Kanami, Tanaka, Miwa, Nakamura, Takuro, Semba, Kentaro, Yamori, Takao, Yaguchi, Shin-ichi, Dan, Shingo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205545/
https://ncbi.nlm.nih.gov/pubmed/30416685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26216
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller